Clinical Trial

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Study acronym: REACT
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated April 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-02-28; most recent amendment 2025-12-15.
Trial Details
NCT Number NCT06294600
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions Community-acquired Pneumonia
Enrollment 330 participants
Start Date 2024-02-12
Primary Completion 2026-04-05 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-16